Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients

Authors: Hua-Zhen Tan, Zhi-Yong Wu, Jian-Yi Wu, Lin Long, Ji-Wei Jiao, Yu-Hui Peng, Yi-Wei Xu, Shan-Shan Li, Wei Wang, Jian-Jun Zhang, En-Min Li, Li-Yan Xu

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

SLC52A3 was recently identified as a susceptibility gene for esophageal squamous cell carcinoma (ESCC). However, associations between the single nucleotide polymorphisms (SNPs) rs13042395 (C > T) and rs3746803 (G > A) in SLC52A3 and risk, tumor characteristics and survival of ESCC patients remain inconclusive and of unknown prognostic significance.

Methods

Analyses of the association between SNPs in SLC52A3 and ESCC risk were performed on 479 ESCC cases, together with 479 controls, in a case-control study. Blood samples for cases and controls were collected and genotyped by real-time polymerase chain reaction (PCR) using TaqMan assays. Among the 479 ESCC cases, 343 cases with complete clinical data were used to investigate the association between SNPs and ESCC clinical characteristics; 288 cases with complete clinical data and 5-year follow-up data were used to analyze the association between SNPs and prognosis. Dual luciferase reporter assays and electrophoretic mobility shift assays (EMSAs) were used to investigate the biological function of rs13042395.

Results

No association was found between SLC52A3 rs3746803 and susceptibility, tumor characteristics or survival of ESCC patients. For rs13042395, TT genotype carriers were likely to have reduced lymph node metastasis (odds ratio (OR) = 0.55, 95 % confidence interval (CI), 0.31–0.98) and longer relapse-free survival time (P = 0.03) . Also, both rs13042395 (hazard ratio (HR) = 0.62, 95 % CI, 0.38–0.99) and regional lymph node metastasis (HR = 2.06, 95 % CI, 1.36–3.13 for N1 vs. N0; HR = 2.88, 95 % CI, 1.70–4.86 for N2 vs. N0; HR = 2.08, 95 % CI, 1.01–4.30 for N3 vs. N0) were independent factors affecting relapse-free survival for ESCC patients who underwent surgery. Dual luciferase reporter assays and EMSAs suggested that the CC genotype of rs13042395 enhanced SLC52A3 expression, probably via binding with specific transcription factors.

Conclusions

The rs13042395 polymorphism in SLC52A3 is associated with regional lymph node metastasis and relapse-free survival in ESCC patients.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.PubMedPubMedCentral
3.
4.
5.
6.
Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133(5):486–94.CrossRefPubMed
7.
Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010;42(9):764–7.CrossRefPubMedPubMedCentral
8.
Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 2010;42(9):759–63.CrossRefPubMed
9.
Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet. 2011;43(7):679–84.CrossRefPubMed
10.
Abnet CC, Wang Z, Song X, Hu N, Zhou FY, Freedman ND, et al. Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet. 2012;21(9):2132–41.CrossRefPubMedPubMedCentral
11.
Wu C, Wang Z, Song X, Feng XS, Abnet CC, He J, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet. 2014;46(9):1001–6.CrossRefPubMedPubMedCentral
12.
Yamamoto S, Inoue K, Ohta KY, Fukatsu R, Maeda JY, Yoshida Y, et al. Identification and functional characterization of rat riboflavin transporter 2. J Biochem. 2009;145(4):437–43.CrossRefPubMed
13.
Fujimura M, Yamamoto S, Murata T, Yasujima T, Inoue K, Ohta KY, et al. Functional characteristics of the human ortholog of riboflavin transporter 2 and riboflavin-responsive expression of its rat ortholog in the small intestine indicate its involvement in riboflavin absorption. J Nutr. 2010;140(10):1722–7.CrossRefPubMed
14.
Jiang XR, Yu XY, Fan JH, Guo L, Zhu C, Jiang W, et al. RFT2 is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenesis by sustaining cell proliferation and protecting against cell death. Cancer Lett. 2014;353(1):78–86.CrossRefPubMed
15.
Ji A, Wang J, Yang J, Wei Z, Lian C, Ma L, et al. Functional SNPs in human C20orf54 gene influence susceptibility to esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2011;12(12):3207–12.PubMed
16.
Ji A, Ma L, Yang J, Xu Y, Wang J, Lian C, et al. The functional SNP rs3746804 in C20orf54 modifies susceptibility to esophageal squamous cell carcinoma. Oncol Res Treat. 2014;37(11):654–7.CrossRefPubMed
17.
Gu H, Ding G, Zhang W, Liu C, Chen Y, Chen S, et al. Replication study of PLCE1 and C20orf54 polymorphism and risk of esophageal cancer in a Chinese population. Mol Biol Rep. 2012;39(9):9105–11.CrossRefPubMed
18.
Palmer AJ, Lochhead P, Hold GL, Rabkin CS, Chow WH, Lissowska J, et al. Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev. 2012;21(6):541–4.CrossRefPubMedPubMedCentral
19.
Dura P, Bregitha CV, te Morsche RH, Roelofs HM, Kristinsson JO, Wobbes T, et al. GWAS-uncovered SNPs in PLCE1 and RFT2 genes are not implicated in Dutch esophageal adenocarcinoma and squamous cell carcinoma etiology. Eur J Cancer Prev. 2013;22(5):417–9.CrossRefPubMed
20.
Piao JM, Shin MH, Kim HN, Song HR, Kweon SS, Choi JS, et al. Replication of results of genome-wide association studies on esophageal squamous cell carcinoma susceptibility loci in a Korean population. Dis Esophagus. 2014;27(8):798–801.CrossRefPubMed
21.
Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–8.CrossRefPubMed
22.
Xu Y, Chen Q, Yu X, Zhou X, Zheng X, Mao W. Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases. Oncol Lett. 2013;5(1):185–90.PubMed
23.
Lorenz D, Origer J, Pauthner M, Graupe F, Fisseler-Eckhoff A, Stolte M, et al. Prognostic risk factors of early esophageal adenocarcinomas. Ann Surg. 2014;259(3):469–76.CrossRefPubMed
24.
Yang CS, Miao J, Yang W, Huang M, Wang T, Xue H, et al. Diet and vitamin nutrition of the high esophageal cancer risk population in Linxian. China Nutr Cancer. 1982;4(2):154–64.CrossRefPubMed
25.
van Rensburg SJ, Benade AS, Rose EF, du Plessis JP. Nutritional status of African populations predisposed to esophageal cancer. Nutr Cancer. 1983;4(3):206–16.CrossRefPubMed
26.
Guo WD, Li JY, Blot WJ, Hsing AW, Chen JS, Fraumeni Jr JF. Correlations of dietary intake and blood nutrient levels with esophageal cancer mortality in China. Nutr Cancer. 1990;13(3):121–7.CrossRefPubMed
27.
Siassi F, Ghadirian P. Riboflavin deficiency and esophageal cancer: a case control-household study in the Caspian Littoral of Iran. Cancer Detect Prev. 2005;29(5):464–9.CrossRefPubMed
28.
Webster RP, Gawde MD, Bhattacharya RK. Modulation of carcinogen-induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett. 1996;98(2):129–35.CrossRefPubMed
29.
Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85(18):1483–92.CrossRefPubMed
30.
Dawsey SM, Wang GQ, Taylor PR, Li JY, Blot WJ, Li B, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev. 1994;3(2):167–72.PubMed
31.
Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev. 1994;3(2):161–6.PubMed
32.
He Y, Ye L, Shan B, Song G, Meng F, Wang S. Effect of riboflavin-fortified salt nutrition intervention on esophageal squamous cell carcinoma in a high incidence area, China. Asian Pac J Cancer Prev. 2009;10(4):619–22.PubMed
Metadata
Title
Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients
Authors
Hua-Zhen Tan
Zhi-Yong Wu
Jian-Yi Wu
Lin Long
Ji-Wei Jiao
Yu-Hui Peng
Yi-Wei Xu
Shan-Shan Li
Wei Wang
Jian-Jun Zhang
En-Min Li
Li-Yan Xu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2588-3

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain

Study protocol

A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer

Research article

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

Study protocol

Design of a multicentre randomized controlled trial to evaluate the effectiveness of a tailored clinical support intervention to enhance return to work for gastrointestinal cancer patients

Case report

A case of lymphangioleiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus

Research article

Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits